BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most promising future stocks to buy now. Piper Sandler revised the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $84 from $122 on February 6 and maintained an Overweight rating on the shares. BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds is Buying In another development, Barclays assumed coverage of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with an Overweight rating and an $80 price target on Ja ...

In this article, we will look at the 13 Most Promising Future Stocks to Buy Now.On February 6, Josh Belton, Gabelli Funds portfolio manager for growth equities, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends, his perspective on where AI is generating revenue in today’s market, and the effects of AI on software. He stated that the market has an “interesting irony” at present, with fears regarding AI being a bubble and AI investments not generating returns looming. At the same time, AI ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Best Cheap Stocks to Buy Right Now. Barclays initiated coverage of BioMarin on January 28, assigning it an “Overweight” rating and a target price of $80. This target price implies a 41.5% upside from the current price. The firm’s analyst notes that the company’s acquisition plans and “strong fundamentals” are key reasons for their overweight call. Barclays Initiates Coverage on BioMarin Pharmaceutical (BMRN), with an Overweight Call One of those ac ...

Savant Capital LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 54.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,827 shares of the biotechnology company’s stock after purchasing an additional 29,174 shares during the period. Savant Capital LLC’s holdings in BioMarin Pharmaceutical were worth $4,486,000 as of its most recent SEC filing. Get BioMarin Pharmaceu ...

Group 1 - The Biotech Forum facilitates discussions on specific covered call trades and offers a model portfolio of attractive biotech stocks [1] - Bret Jensen, with over 13 years of experience as a market analyst, leads The Biotech Forum, focusing on high beta sectors with potential for large investor returns [2] - The investing group provides a model portfolio featuring 12-20 high upside biotech stocks, along with live chat for trade ideas and weekly market commentary [2] Group 2 - The analyst has disclosed a beneficial long position in the shares of BMRN, FOLD, and TVTX through various means [3] - Seeking Alpha emphasizes that past performance does not guarantee future results and that no specific investment recommendations are provided [4]

Core Viewpoint - BioMarin Pharmaceutical is expected to report its Q4 and full-year 2025 results soon, with potential strong performance from its rare-disease drug Voxzogo, but there are also concerns regarding competition and revenue guidance [1][2][3][10]. Financial Performance - BioMarin's CFO indicated that Voxzogo revenue is projected to reach its highest level in Q4, contributing to an optimistic outlook for the quarter [2]. - The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting double-digit year-over-year growth expectations [3]. Upcoming Catalysts - The FDA has set a PDUFA date of February 28, 2026, for Palynziq's approval for adolescents with phenylketonuria, with potential EU approval also expected in the first half of the year [4]. - BioMarin plans to announce results from two Phase 3 clinical studies in the first half of 2026 and intends to file for full FDA approval of Voxzogo for achondroplasia [5]. Market Data - BioMarin's current market capitalization is $11 billion, with a gross margin of 80.64% [7]. - The stock is currently trading at $56.51, with a day's range of $55.30 to $56.72 [6][7]. Investment Considerations - There are reasons to be cautious, including reliance on large contracted ex-U.S. orders for Voxzogo, which if not fulfilled, could lead to missing Q4 estimates [8]. - Long-term uncertainty exists regarding Voxzogo's market position due to potential competition, which could impact future revenue projections [9]. - The acquisition of Amicus Therapeutics is seen as a potential growth booster, but waiting to invest may be prudent given current uncertainties [10].

SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the "Notes"). The issue price of the Notes is 100.000%. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions. BioMarin also announced that, in connection with the pending acquisition (the "Acquisition") of Amicus Thera ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the best large cap stocks under $100 with huge upside potential. On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy. She also raised her price target estimate from $84 to $98, offering an upside of almost 75% from the prevailing level. Illumina (ILMN) Jumps 24.8% on Earnings Beat RAJ CREATIONZS / shutterstock.com Ijem’s upward revisions are based on the company’s encouraging fundam ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Cheap Stocks with Huge Upside Potential. On January 20, Canaccord Genuity raised BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) price target from $84 to $98, implying 74.4% upside from the current share price. On January 13, Wedbush analyst Yun Zhong reaffirmed his Buy rating on the stock while maintaining a price target of $94. Yun Zhong’s Buy rating is based on several factors that reinforce the company’s ability to deliver sustained long-term gro ...

Core Viewpoint - BioMarin Pharmaceutical Inc. is planning to raise $850 million through the issuance of senior unsecured notes due in 2034 to finance its acquisition of Amicus Therapeutics, Inc. and related expenses [1][3]. Financing Details - The company is launching a $2 billion senior secured term loan "B" facility in addition to an existing $800 million senior secured term loan "A" facility and a $600 million senior secured revolving credit facility to support the acquisition [2]. - The net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will be used to fund the acquisition and associated fees [3]. Redemption Conditions - Gross proceeds from the notes will be held in an escrow account until the acquisition is completed, with a mandatory redemption clause if the acquisition is not finalized by December 19, 2026 [4]. Guarantees and Covenants - The notes will be guaranteed by certain subsidiaries of BioMarin, including Amicus post-acquisition, and will include customary covenants that restrict additional debt incurrence and other financial activities [5][6]. Regulatory Information - The notes will not be registered under the Securities Act and will be offered only to qualified institutional buyers or non-U.S. persons, subject to transfer restrictions [7]. Company Overview - BioMarin is a global biotechnology company focused on rare diseases, with a strong portfolio of commercial therapies and a robust pipeline for drug development [9][10].